Peptide Academy · Metabolic

Tirzepatide

Also known as Dual GIP/GLP-1 agonist

Educational research summary, not medical advice. Many compounds here are not approved for human use. Talk to a licensed clinician before making any health decision.

The Peptide Academy is free to read. Members also get the research protocols for Tirzepatide, dose and vial tracking, and an AI Advisor with cited sources. Try it all free for 7 days, no card needed.

Start my free 7-day trial

What is Tirzepatide?

A dual incretin agonist with the strongest published weight-loss outcomes of the class.

How it works

Simultaneously activates GIP and GLP-1 receptors, improving insulin sensitivity and lipid handling beyond GLP-1 alone.

Published research

SURMOUNT-1: up to 20.9% mean weight reduction at 72 weeks
SURPASS program for HbA1c reduction in type 2 diabetes

Cautions

Prescription medication. Requires clinical supervision and nutrition support.

Side effects & fixes

Common side effects

—Nausea, especially in the first days after starting or raising the dose
—Diarrhea or constipation
—Reduced appetite, early fullness, burping or reflux
—Fatigue and lightheadedness when eating very little
—Mild redness or itching at the injection site

Histamine reactions

Uncommon. Mild injection-site redness or itching can occur; widespread hives or swelling are rare and need urgent care.

Common fixes

Titrate slowly and stay longer at a dose that causes nausea before moving up.
Eat small, low-fat meals, stop at the first sign of fullness, and avoid lying down for 2–3 hours after eating.
Drink plenty of fluids with electrolytes; dehydration makes nausea and fatigue worse.
For constipation, add fiber gradually with extra water; for nausea, ginger or bland foods help many people.
Prioritise protein at each meal to protect muscle while appetite is low.
Rotate injection sites (abdomen, thighs, upper arms) and stay at least an inch from the last spot.

Stop and get help

Severe, persistent stomach pain (possibly spreading to the back) — this can signal pancreatitis or gallbladder problems.
Vomiting or diarrhea that stops you keeping fluids down.
Stop and get emergency help for swelling of the face, lips, tongue or throat, trouble breathing, widespread hives, chest pain or fainting.

Basis: Prescribing information and clinical trials for the GLP-1 class. Educational only, not medical advice.

Medication concerns

From FDA prescribing information

Insulin and sulfonylureas (glipizide, glyburide, glimepiride)
Higher risk of low blood sugar when combined. Prescribers often lower these doses at the start; check your glucose more often.
Medicines taken by mouth (especially levothyroxine, antibiotics, seizure medicines and warfarin)
Slower stomach emptying can delay or reduce how they're absorbed, most of all after the first dose and each dose increase. Ask your prescriber whether timing or monitoring should change.
Birth control pills
Tirzepatide can make pills less reliable when starting and raising the dose; see Birth control & pregnancy on this card.
Diuretics, ACE inhibitors or ARBs (lisinopril, losartan) and NSAIDs (ibuprofen, naproxen)
Vomiting or diarrhea can dehydrate you and strain the kidneys, a risk these medicines add to. Keep fluids up and call your clinician if you can't keep liquids down.
Planned surgery, sedation or endoscopy
Tell the anesthesia team you take this. Food can stay in the stomach longer, which raises aspiration risk under anesthesia.
Other GLP-1-type medicines (semaglutide, tirzepatide, liraglutide and similar)
Don't stack two drugs from this class; it multiplies side effects without proven benefit.
Everything else you take, including supplements
Bring a full list of medicines and supplements to your pharmacist or clinician before starting.

Basis: FDA prescribing information for GLP-1 medicines (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide); investigational members of the class are assumed to share these until studied. Educational only, not medical advice. Never stop or change a prescribed medicine without your prescriber.

Birth control & pregnancy

Tirzepatide (Mounjaro, Zepbound)

Tirzepatide can make birth control pills less reliable. It slows stomach emptying, which reduces how much of the pill is absorbed. The effect is largest after the first dose and fades over time.

—The prescribing information advises people on oral hormonal birth control to switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after starting and for 4 weeks after each dose increase.
—In the label's study, one 5 mg dose lowered the peak blood levels of a combined pill's hormones by roughly 55–66% and overall exposure by about 20–23%.
—Non-oral hormonal methods (patch, ring, implant, injection, hormonal IUD) are not expected to be affected.
—Pregnancy: the label says to stop tirzepatide once a pregnancy is recognized.
—Nausea, vomiting and diarrhea are common early side effects. Vomiting or diarrhea soon after taking a birth control pill can reduce how much is absorbed, so ask a pharmacist what your pill's instructions say.

Basis: FDA prescribing information for Zepbound and Mounjaro.

Educational only, not medical advice. Talk with your clinician or pharmacist before changing birth control.

Protocols & tracking are members-only

Members see the research protocols for Tirzepatide, plan schedules, track every dose and vial, and ask the AI Advisor questions with cited sources. Try every Researcher feature free for 7 days, no card needed.

Start my free 7-day trial Reconstitution calculator GLP-1 research guide

More metabolic compounds

Browse all compounds in the Peptide Academy →